EFFECTS OF *SERENOA REPENS* ALCOHOL EXTRACT ON BENIGN PROSTATE HYPERPLASIA

Skender Saidi¹, Sotir Stavridis¹, Oliver Stankov¹, Sasho Dohcev¹, Sasho Panov²

¹ University Clinic of Urology, Skopje, Republic of Macedonia,
² Molecular Biology and Genetics Dept., Faculty of Natural Sciences and Mathematics,
Ss. Cyril & Methodius University, Skopje, Republic of Macedonia

Corresponding author: Skender Saidi, MD, PhD, Address: University Clinic of Urology, Clinical Center, Vodnjanska str. 17, MK-1000, Skopje, Republic of Macedonia; e-mail: skendersaidi@yahoo.com

ABSTRACT

An increasing tendency has recently emerged for the use of phyotherapeutic agents as alternative to commercial pharmacological agents for the treatment of benign prostate hyperplasia (BPH). The purpose of this study is to evaluate the effects of *Serenoa repens* alcohol extract treatment on BPH patients’ symptoms and major parameters during one-year follow-up.

The study was performed on 70 men aged 40 - 79 years (mean 60.58) with symptomatic BPH that were divided into a group of 40 patients treated with *Serenoa repens* extract (SRT) and a control group of 30 patients that received no treatment and were observed only. The following parameters were determined at the time of diagnosis (baseline), and after 6 and 12 months: prostate size, serum prostate-specific antigen (PSA) and uroflowmetry parameters including maximum flow rate (MFR), average flow rate (AFR) and post-voiding residual volume (PVRV). In addition, the relevant patient symptoms were evaluated using the International Prostate Symptom Score (IPSS) system.

The patients in the SRT group showed a statistically significant increment of the average MFR and AFR values and reduction of PV relative to the control group (*p*<0.05). The significant differences between the proportion of patients with prostate volume >40 ml in the SRE treated group vs. control group was observed (*p*<0.05). The mean IPSS score was highly significantly reduced in the SRT group (*p*<0.01).

The mild improvements of the urine flow, prostate size and IPSS score during 12 months treatment with the *Serenoa repens* extract indicate possible efficiency of this phytotherapeutic agent in patients with BPH.

Key words: benign prostate hyperplasia, phytotherapeutics, *Serenoa repens* extract

INTRODUCTION

Benign prostatic hyperplasia (BPH) is very common disorder and is responsible for significant morbidities in male population over 45 years old [1-3]. Numerous studies have shown that BPH is a progressive condition which can have a significant negative impact on patients’ quality of life and if left untreated, can lead to acute urinary retention and chronic renal insufficiency [4-7]. Until about 25 years ago, surgical prostate resection was the only therapeutic opportunity. At that period, pharmacotherapy including α-adrenergic antagonists (α-blockers) and 5-α reductase inhibitors
gradually became the major treatment option for BPH [8]. Although administration of those medications is usually well tolerated, the side effects sometimes become significant or unacceptable for some patients and their efficacy is not always satisfactory [9].

Largely from that reason, an increasing tendency has recently emerged for the use of phytotherapeutic agents as alternative to the commercial pharmacological agents for BPH treatment. The extract of the North American dwarf palm tree *Serenoa repens* is a phytopharmaceutical product that is most commonly used for the treatment of urological symptoms associated with benign prostatic hyperplasia [10]. Moreover, the commercial preparations of this phytotherapeutic agent are increasingly becoming a treatment option, they have a long history of research and relatively well determined mechanisms of action [11-16].

The purpose of this study is to evaluate the effects of *Serenoa repens* alcohol extract on BPH patients’ symptoms and major parameters during a one-year follow-up.

**MATERIALS AND METHODS**

Seventy men aged 40 - 79 years (mean 60.58) with symptomatic BPH were recruited for a one-year follow-up, clinical study. The enrolled patients were assigned either by monotherapy with *Serenoa repens* alcohol extract (SRT group, n=40) or received no treatment and were observed by watchful waiting only, serving as a control group (n=30). The patients from the SRT group were treated with 320 mg/day of commercial *Serenoa repens* alcohol extract (Prostamol Uno, Berlin-Chemie AG).

During the 12-month evaluation period, each patient was examined at the time of the diagnosis (baseline), and after 6 and 12 months. The standard clinical and laboratory examinations were performed including the prostate size i.e. volume (PV) estimation with transabdominal ultrasonography and serum prostate-specific antigen (PSA) determination. Uroflowmetry parameters that were measured were: Maximum flow rate (MFR) and Average flow rate (AFR), both expressed as ml/sec. The post-voiding residual volume (PVR) or the residual urine were measured in milliliters. The relevant patient symptoms were evaluated using the International Prostate Symptom Score (IPSS) system. All diagnostic and patient evaluation procedures were performed following the established clinical practice at the Urology Clinic and according to the European Association of Urology (EAU) Guidelines [17].

The patients of both groups that did not complete the study by any cause were excluded from the calculations. The missing values of any parameter were dealt with by the last observation carried forward method. The null hypothesis was that the investigated herbal supplement treatment does not offer improvement of symptoms and major parameters in BPH patients during 12 month follow-up.

The numerical variables that showed normal distribution were compared between the groups using the unpaired Student’s independent samples t-test. The differences among the independent parameter means derived from the data with skewed distribution were compared between the groups with non-parametric Mann-Whitney test. The comparison of the categorical variables between the two investigated groups of patients was calculated with the Chi-square test.

All statistical tests used were two-tailed; *p*-values ≤0.05 and ≤0.01 were considered significant and highly significant, respectively. Data processing was performed using XLSTAT 2016 and Microsoft Excel 2016.

**RESULTS**

Of the 70 evaluable patients with diagnosed BPH, 40 were continuously treated with *Serenoa repens* alcohol extract during 12 months, while 30 patients received no treatment (watchful waiting) and served as a control group.

The values obtained with the uroflowmetry (MFR, AFR and PVR), laboratory testing (PSA), transabdominal ultrasonography (PV) and patient evaluation (IPSS) in both SRT-treated and in the control group at baseline, as well as after 6 and 12 months, were represented in Table 1 and Figure 1.

Error bars represents ± S.E. Abbreviations: SRT, *Serenoa repens* treated group; CTR, control group - watchful waiting; MFR, maximum flow rate; AFR, average flow rate; PV, prostate volume; PVR, post voiding residual volume; PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score.

Table 2 provides the group mean changes in the analyzed clinical and laboratory parameters in both patient groups at 6 and 12 months regarding the corresponding baseline values, as well as the statistical significance expressed by the calculated *p*-values.
Effects of Serenoa repens alcohol extract on benign prostate hyperplasia

Patients in the Serenoa repens treated group showed a statistically significant increase of the average MFR and AFR values over 12 months of treatment relative to the control group where the opposite tendency was registered, nevertheless the values were clinically negligible. The post-voiding residual volume was not statistically significantly different between the treated and the control group.

**Table 1.** Mean values of the analyzed parameters in both patient groups from baseline to 6 and 12 months

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SRT group (n=40)</th>
<th>Control group (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MFR (ml/sec)</td>
<td>Baseline 13.27 ± 0.93</td>
<td>14.03 ± 0.91</td>
</tr>
<tr>
<td></td>
<td>6 months 13.78 ± 0.88</td>
<td>14.22 ± 1.06</td>
</tr>
<tr>
<td></td>
<td>12 months 14.03 ± 0.91</td>
<td>13.69 ± 1.11</td>
</tr>
<tr>
<td>AFR (ml/sec)</td>
<td>Baseline 7.79 ± 0.48</td>
<td>7.97 ± 0.57</td>
</tr>
<tr>
<td></td>
<td>6 months 7.75 ± 0.46</td>
<td>8.16 ± 0.51</td>
</tr>
<tr>
<td></td>
<td>12 months 8.16 ± 0.51</td>
<td>7.50 ± 0.55</td>
</tr>
<tr>
<td>PVR (ml)</td>
<td>Baseline 19.20 ± 4.86</td>
<td>15.13 ± 4.77</td>
</tr>
<tr>
<td></td>
<td>6 months 13.00 ± 4.38</td>
<td>2.00 ± 1.19</td>
</tr>
<tr>
<td></td>
<td>12 months 15.13 ± 4.77</td>
<td>2.90 ± 1.64</td>
</tr>
<tr>
<td>PSA (ng/ml)</td>
<td>Baseline 2.24 ± 0.34</td>
<td>2.22 ± 0.35</td>
</tr>
<tr>
<td></td>
<td>6 months 2.22 ± 0.35</td>
<td>2.17 ± 0.35</td>
</tr>
<tr>
<td></td>
<td>12 months 2.22 ± 0.35</td>
<td>2.35 ± 0.27</td>
</tr>
<tr>
<td>PV (ml)</td>
<td>Baseline 38.11 ± 1.94</td>
<td>38.95 ± 2.05</td>
</tr>
<tr>
<td></td>
<td>6 months 38.95 ± 2.05</td>
<td>38.95 ± 2.17</td>
</tr>
<tr>
<td></td>
<td>12 months 38.95 ± 2.17</td>
<td>37.27 ± 2.50</td>
</tr>
<tr>
<td>IPSS (score)</td>
<td>Baseline 11.35 ± 0.34</td>
<td>9.30 ± 0.55</td>
</tr>
<tr>
<td></td>
<td>6 months 9.15 ± 0.53</td>
<td>9.60 ± 0.46</td>
</tr>
<tr>
<td></td>
<td>12 months 9.30 ± 0.55</td>
<td>9.63 ± 0.52</td>
</tr>
</tbody>
</table>

The values are expressed as mean ± S.E.

**Table 2.** Comparison of the analyzed parameters differences in both patient groups after 6 and 12 months follow-up

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SRT group (n=40)</th>
<th>Control group (n=30)</th>
<th>Difference between the two groups p</th>
</tr>
</thead>
<tbody>
<tr>
<td>MFR (ml/sec)</td>
<td>Mean change from baseline to 6 months 0.51 ± 0.40</td>
<td>Mean change from baseline to 12 months -0.53 ± 0.29</td>
<td>0.011 *</td>
</tr>
<tr>
<td>AFR (ml/sec)</td>
<td>Mean change from baseline to 6 months -0.03 ± 0.24</td>
<td>Mean change from baseline to 12 months -0.29 ± 0.14</td>
<td>0.002 *</td>
</tr>
<tr>
<td>PVR (ml)</td>
<td>Mean change from baseline to 6 months 19.20 ± 4.86</td>
<td>Mean change from baseline to 12 months 2.00 ± 1.19</td>
<td>0.063</td>
</tr>
<tr>
<td>PSA (ng/ml)</td>
<td>Mean change from baseline to 6 months -0.03 ± 0.09</td>
<td>Mean change from baseline to 12 months 0.12 ± 0.12</td>
<td>0.060</td>
</tr>
<tr>
<td>PV (ml)</td>
<td>Mean change from baseline to 6 months +0.84 ± 0.24</td>
<td>Mean change from baseline to 12 months +0.92 ± 0.28</td>
<td>0.016 *</td>
</tr>
<tr>
<td>IPSS (score)</td>
<td>Mean change from baseline to 6 months -2.20 ± 0.41</td>
<td>Mean change from baseline to 12 months -2.05 ± 0.47</td>
<td>0.00011 *</td>
</tr>
</tbody>
</table>

The values are expressed as mean change ± S.E.; *, statistically significant (p < 0.05)

**Uroflowmetry**

Patients in the Serenoa repens treated group showed a statistically significant increase of the average MFR and AFR values over 12 months of treatment relative to the control group where the opposite tendency was registered, nevertheless the values were clinically negligible. The post-voiding residual volume was not statistically significantly different between the treated and the control group.

**PSA**

Serum PSA levels were similar at baseline, as well as after 6 and 12 months of follow-up. The
mean PSA values were not significantly different between the two groups ($p>0.05$).

**Prostate size**
Both treated and control groups showed a very small, but gradual increase of the prostate volume during the 12-moths follow-up, although this seems to be of limited, if any, clinical importance. However, this PV increasing tendency was milder in the SRT group and the difference between the two investigate groups is statistically significant ($p<0.05$). There were significant differences between the proportion of patients with prostate volume $>40$ ml was 37.50% in the *Serenoa repens* treated group vs. 46.67% in the control group (Chi-square test, $p<0.05$).

**Urinary symptom scores**
The mean IPSS score was significantly reduced in the *Serenoa repens* treated group from baseline to 6 and 12 months, but not in the control patient group. The observed differences were statistically highly significant and may reflect a clinically noticeable improvement in the patients treated with *Serenoa repens* alcohol extract.

**DISCUSSION**
Patients with symptomatic BPH are usually treated with α-blockers as a first-line therapy option. However, the patients with mild symptoms and in those who are not anxious by their symptoms might be managed with watchful waiting (i.e. active surveillance), according to the American Urology Association [18]. In our study, we have enrolled a population of 70 patients that fulfill the above recommendation for watchful waiting and divided them into two groups: SRT group treated with commercial *Serenoa repens* extract and a control groups with no medical treatment. Clinical and laboratory examinations were performed at the beginning of the study, and 6 and 12 months later.

We observed that the parameters measured by uroflowmetry (MFR, AFR and PVR) were either insignificantly changed during the 1-year follow-up or no differences were found between the SRT and the control groups of patients. Similarly, the serum PSA levels remain nearly unaffected regarding to baseline values in both SRT and control groups, which is comparable to some previous studies. In a recent randomized, placebo-controlled, double blind multi-centered CAMUS trial conducted on 369 men with BPH, *Serenoa repens* extract does not affect serum PSA levels more than placebo [19].

On the contrary, the prostate size increase during the 1-year follow-up and the proportion of patients with prostate volume $>40$ ml was significantly higher in the control groups than in the SRT group indicating a measurable effect on this important BPH parameter.

We observed significant reduction of the mean IPSS score in the *Serenoa repens* extract treated patients, which is even more prominent considering the initially registered higher IPSS score at baseline in the SRT group. This indicates that there is clinically evident improvement in the patients’ symptoms related to BPH in the treated patients. Although the changes in the validated urological symptom scores in SRT group were highly significant ($p<0.01$) regarding the control group, no patient had a clinically important improvement ($\geq 3$ points) on the IPSS score scale.

Our results are consistent with some of the previously published studies in which noticeable reduction of the lower urinary tract symptoms associated with BPH and significant improvement of life quality with less decrease in sexual function was detected [20]. The clinical responses to phytotherapy with *Serenoa repens* extracts are found to be very promising in other studies, too [21, 22]. Some authors describes the improvement in erectile function and decreasing complications following transurethral resection of the prostate, especially bleeding [23]. EAU guidelines state that this herbal extracts significantly reduce nocturia in comparison with placebo [17]. On the contrary, some authors described that *Serenoa repens* extracts have not shown more effectiveness than placebo in the treatment of BPH [24-26]. However, more recent data favor the use of *Serenoa repens* extracts in milder BPH cases with promising results [27].

The mechanisms of pharmacological action of *Serenoa repens* extracts in BPH have not been fully understood yet, though they have been extensively studied. The current research indicates that active components of this extract lead to inhibition of 5α-reductase and have anti-androgenic, anti-inflammatory, anti-proliferative and anti-edematous effects on the prostate cells [15]. At molecular level, binding to the receptors in the lower urinary tract, including the α1-adrenergic receptors, muscarinic acetylcholine receptors, 1,4-dihydropyridine receptors and vanilloid receptors was observed [28]. In addition, it seems that the anti-inflammatory effects *Serenoa repens* extracts
are mediated by modulation of the expression of inflammation related-genes, while anti-androgenic effects are primarily due to the inhibition of type 1 and type 2 isoenzymes of 5α-reductase [12, 13]. It should be noted that the extraction methods also have an impact on the pharmacological action in BPH and this may be one of the major reasons for studies’ inconsistencies [14, 29].

No serious adverse events or interactions with co-administered drugs have been described during the use of *Serenoa repens* extracts and this phytotherapy is associated with less sexual dysfunction-related side effects than the usual drug therapy for BPH as tamsulosin or finasteride [30].

A limitation of the present study is that it was not randomized considering the current protocol’s opportunity to observe only the patients with BPH under strict inclusion and exclusion criteria. Larger studies with longer follow-up are needed to further evaluate the potential efficiency of this phytotherapeutics for BPH as an alternative to the established pharmaceutical agents and to evaluate the possible side effects due to the long-term use.

**CONCLUSION**

In our clinical study, the patients treated with *Serenoa repens* extract (320 mg/day) showed a significant increase of the uroflowmetry parameters, but this seems to be of marginal clinical importance. The levels of serum PSA remained virtually unchanged in both groups during the follow-up. We found that the prostate size increase and the proportion of patients with prostate volume >40 ml was significantly lower in the SRT group than in the control groups during the 1-year follow-up. The mean IPSS score was noticeably reduced in the *Serenoa repens* treated group, which reflects the lower urinary tract symptoms.

The mild improvements of the urine flow, prostate size and IPSS score during 12 months treatment with the SRE indicate possible efficiency of this phytotherapeutic agent in patients with BPH.

**REFERENCES**


EFFECTS OF SERENOA REPENS ALCOHOL EXTRACT ON BENIGN PROSTATE HYPERPLASIA

Скендер Саиди¹, Сотир Ставридис¹, Оливер Станков¹, Сашо Дохчев¹, Сашо Панов²

¹ Универзитеска клиника за урологија, Скопје
² Одделение за молекуларна биологија и генетика, Институт за биологија, Природно-математички факултет, Универзитет Св. Кирил и Методиј, Скопје

Резиме

Во последниве години забележана е растечка тенденција на употреба на фитотерапевтичите како алтернатива на комерцијалните фармаколошки агенси при третманот на бенигната простатна хиперплазија (БПХ). Целта на оваа студија е да ги евалуира ефектите на алкохолниот екстракт од Serenoa repens врз симптомите кај пациентите со БПХ и врз основните параметри во текот на едногодишно клиничко следење.

Истражувањето е извршено врз 70 мажи со возраст во опсег од 40 - 79 години (просек 60,58) со симптоматска БПХ кои беа поделени во две групи: група СРТ составена од 40 пациенти третирани со екстракт од Serenoa repens и контролна група од 30 пациенти кои не примаа терапија, односно беа исклучиво клинички следени. Следниве парамтери беа определувани при поставувањето на дијагнозата (појдовна точка), како и 6, односно 12 месеци подоцна: волумен на простатата, серумскиот простатно-специфичен антиген (PSA), како и урофлоуметриските параметри кои вклучуваа максимална брзина на проток на урината (MFR), просечен брзина на проток (AFR) и волуменот на заостаната урина по празнењето на мочниот меур (PVRV). Покрај тоа, релевантните симптоми кај пациентите беа евалуирани користејќи го интернационалниот систем на бодување на симптомите на простатата (IPSS).

Кај пациентите од СРТ-групата е регистрирано статистички значајно зголемување на просечните вредности на MFR и AFR и намалување на PV во однос на тие кај контролната група. Забележани се сиграфикиантни разлики меѓу застаненоста на пациентите со волумен на простатата >40 ml кај СРТ-групата, наспроти контролната група. Просечните IPSS-бодови беа високо сигнафикиантно намалени кај СРТ-групата.

Умереното подобрување на протокот на урината, волуменот на простатата и на IPSS-бодовите во текот на 12-месечниот третман со екстракт од Serenoa repens укажуваат на возмозна ефективност на овој фитотерапевтски агенс кај пациентите со БПХ.

Ключни зборови: бенигна простатна хиперплазија, питаотерапевтици, екстракт на Serenoa repens